Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524058 | 1.00 | PDE5A (0.38) | PDE5ANOS1NOS3HRH4PDE2A | |
| SCHEMBL5025402 | 0.88 | TERT (0.36) | PDE3BPDE3APDE10ASMPD3MEN1 | |
| SCHEMBL5025406 | 0.88 | TERT (0.36) | PDE3BPDE3APDE10ASMPD3MEN1 | |
| SCHEMBL5524364 | 0.87 | MEN1 (0.35) | PDE3BPDE3APDE10ASMPD3MEN1 | |
| SCHEMBL5524360 | 0.87 | MEN1 (0.35) | PDE3BPDE3APDE10ASMPD3MEN1 | |
| SCHEMBL5522947 | 0.86 | PDE3B (0.40) | NOS1NOS3DRD4TMEM97SIGMAR1 | |
| SCHEMBL5522937 | 0.86 | PDE3B (0.40) | NOS1NOS3DRD4TMEM97SIGMAR1 | |
| SCHEMBL5036285 | 0.84 | MAOB (0.40) | NOS1NOS3DRD4TMEM97SIGMAR1 | |
| SCHEMBL5036288 | 0.84 | MAOB (0.40) | NOS1NOS3DRD4TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6377291 | 0.83 | MAOB (0.39) | NOS1NOS3DRD4TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166589-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | KLUG MICHAEL G | 2006-07-06 | — | — | US | disclosed |
| US-7064134-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | KLUG MICHAEL G | 2006-03-23 | — | — | US | disclosed |
| US-7012073-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040259858-A1 | Quinoline derivatives | KLUG MICHAEL G (US) | 2004-12-23 | — | — | US | disclosed |
| US-6787558-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS, FOR TREATING ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS AND OBESITY | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| EP-1432421-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030158179-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003028726-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158179-A1 | Quinoline derivatives | RAB1A, GLS, REN | PDE5A 1493/4885NOS1 469/4885NOS3 497/4885 |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | NPY1R, NPY2R, NPY4R | PDE5A 1289/4885NOS1 597/4885NOS3 513/4885 |
| US-20040259858-A1 | Quinoline derivatives | RAB1A, GLS, REN | PDE5A 1493/4885NOS1 469/4885NOS3 497/4885 |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | NPY1R, NPY2R, NPY4R | PDE5A 1689/4885NOS1 713/4885NOS3 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.